ArticleFrontiers in pharmacology2023

Effect of anti-obesity agent HSG4112 on overweight and obese patients following 12 weeks of oral treatment: a study protocol for a randomised, double-blind, placebo-controlled, parallel-group, phase 2a clinical trial.

Kyungha Min et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.